| Bruce Bynum, PHARMACIST | |
|
626 Olive St Sw, Cullman, AL 35055-5594 | |
| (256) 739-3390 | |
| (256) 739-9125 |
| Full Name | Bruce Bynum |
|---|---|
| Gender | Male |
| Speciality | Pharmacist |
| Location | 626 Olive St Sw, Cullman, Alabama |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306213434 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 11359 (Alabama) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Bruce Bynum, PHARMACIST 626 Olive St Sw, Cullman, AL 35055-5594 Ph: (256) 739-3390 | Bruce Bynum, PHARMACIST 626 Olive St Sw, Cullman, AL 35055-5594 Ph: (256) 739-3390 |
News Archive
BaroFold, Inc. today announced that it has entered into an agreement to exclusively license its PreEMT™ Technology to Nuron Biotech for the development of BaroFeron™ and follow-on interferon beta products. BaroFeron is a proprietary recombinant human interferon beta being developed for the treatment of multiple sclerosis. Specific terms of the agreement are not disclosed.
The current study published on the preprint server bioRxiv aims to understand how these compounds affect SARS-CoV-2 in vitro. The researchers from Aarhus University in Denmark examined 11 natural PEIs, with a single synthetic analog, screening them for inhibitory activity against the CPE of SARS-CoV-2 infecting cultured cells with overexpression of TMPRSS2, a serine protease that is instrumental in cleaving the spike protein of the virus.
A new study led by researchers at the University of Southern California (USC) identifies how genes are silenced in cancer cells through distinct changes in the density of nucleosomes within the cells.
The future of disease diagnosis may lie in a "breathalyzer"-like technology currently under development at the University of Wisconsin-Madison.
Pancreatic cancer kills more than 40,000 people every year, and among cancers it's particularly insidious. For 80 percent of patients, the disease is already so advanced at the time of diagnosis that treatment is unlikely to provide significantly life-extending benefits. For patients diagnosed with localized pancreatic cancer, the five-year survival rate remains barely above 20 percent, according to the National Cancer Institute.
› Verified 6 days ago
Mrs. Roxanne E Mauldin, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1910 Main Ave Sw, Cullman, AL 35055 Phone: 256-734-1662 Fax: 256-737-0682 | |
Dr. Stephanie Brooke Matthews, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2104 Al Highway 157, Cullman, AL 35058 Phone: 256-734-3416 | |
Dr. Anna Usaha Intraboona, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 626 Olive St Sw, Cullman, AL 35055 Phone: 256-739-3390 | |
Ms. Rita Kay Freeman, RPHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1701 Main Ave Sw, Suite C, Cullman, AL 35055 Phone: 256-737-3773 Fax: 256-737-3775 | |
Dr. Hunter Dale Cunningham, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1104 Cullman Shopping Ctr Nw, Cullman, AL 35055 Phone: 256-736-7005 | |
Kelly Gerrard, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 2nd Ave Sw, Cullman, AL 35055 Phone: 256-734-7188 | |
Mrs. Cynthia Hayslette Doggett, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1731 2nd Ave Sw, Cullman, AL 35055 Phone: 205-734-8935 Fax: 205-734-3430 |